Skip to content

Ex vivo Identification of Specific Gene Vector Capsids for Liver-Metastases-targeted Gene Therapy with Adeno-associated Viral Vectors The AAV Augsburg-Hamburg oncology interventional (AH-OI) Trial 03

Ex vivo Identification of Specific Gene Vector Capsids for Liver-Metastases-targeted Gene Therapy with Adeno-associated Viral Vectors The AAV Augsburg-Hamburg oncology interventional (AH-OI) Trial 03 - AAV-AH-OI-03

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00036729
Enrollment
24
Registered
2025-04-30
Start date
2025-06-27
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C78.7

Interventions

Sponsors

Universitätsklinikum Augsburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - previously untreated liver metastasis from colorectal cancer with indication for a hemihepatectomy - size of the metastasis to be resected = 1,5 cm - ability to understand the protocol and give informed consent

Exclusion criteria

Exclusion criteria: - medical or psychological impairments or legal restrictions resulting in reduced capability to give informed consent - lack of any of the listed inclusion criteria - if the pathologist determines, that the integrity of the vascular system of the resected tissue has been compromised (e.g. through surgery or intraoperative biopsy for rapid histopathological workup) rendering perfusion impossible, the patient will be excluded - if histopathological workup after the library perfusion will unexpectedly yield a diagnosis other than the expected cancer entity, the patient will be excluded from the trial

Design outcomes

Primary

MeasureTime frame
Feasibility of the procedure to identify specific vector capsid-displayed peptides targeting human liver metastasis ex vivo.

Secondary

MeasureTime frame
Identification of vector-displayed peptides targeting human liver metastasis ex vivo.

Countries

Germany

Contacts

Public ContactMartin Trepel

Universitätsklinikum Augsburg

martin.trepel@uk-augsburg.de+49 821 400 2353

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026